{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:23:19Z","timestamp":1769005399901,"version":"3.49.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["100DHA0500062"],"award-info":[{"award-number":["100DHA0500062"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188999","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T23:27:24Z","timestamp":1512084444000},"page":"e0188999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma"],"prefix":"10.1371","volume":"12","author":[{"given":"Yao-Kuang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Ling","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sz-Iuan","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi-Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Zen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4315","authenticated-orcid":true,"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"LA Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"EG Giannini","year":"2015","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"AL Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s12072-010-9249-4","article-title":"Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma","volume":"5","author":"S Ogasawara","year":"2011","journal-title":"Hepatol Int"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1097\/MD.0000000000000688","article-title":"Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice","volume":"94","author":"IC Lee","year":"2015","journal-title":"Medicine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"M Reig","year":"2013","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3748\/wjg.v20.i1.235","article-title":"Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma","volume":"20","author":"JE Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"AX Zhu","year":"2014","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1007\/s10637-012-9808-8","article-title":"Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease","volume":"30","author":"T Yau","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"JM Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"10064","key":"ref14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"JM Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival","volume":"37","author":"JM Llovet","year":"2003","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ajco.12081","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review","volume":"9","author":"Y Zhao","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s11605-016-3285-x","article-title":"Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma","volume":"20","author":"Y Zhao","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1440-1746.2010.06341.x","article-title":"Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?","volume":"26","author":"DJ Yoo","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma","volume":"13","author":"K Uka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"ref21","first-page":"519783","article-title":"APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review","volume":"2011","author":"CH Tan","year":"2011","journal-title":"Int J Hepatol"},{"key":"ref22","article-title":"Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1681\/ASN.2007121354","article-title":"The secret of immortal time bias in epidemiologic studies","volume":"19","author":"SZ Shariff","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.28266","article-title":"Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation","volume":"63","author":"TY Lee","journal-title":"Hepatology"},{"issue":"Suppl 5","key":"ref25","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/annonc\/mdq166","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"S Jelic","year":"2010","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis","volume":"16","author":"CS Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study","volume":"18","author":"J Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/ans.12803","article-title":"Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis","volume":"86","author":"JJ Leng","year":"2016","journal-title":"ANZ J Surg"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-230X-13-60","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis","volume":"13","author":"TC Xue","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s12032-011-0145-0","article-title":"Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification","volume":"29","author":"ZJ Niu","year":"2012","journal-title":"Med Oncol"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"JP Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e113926","DOI":"10.1371\/journal.pone.0113926","article-title":"Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases","volume":"9","author":"JJ Yoo","year":"2014","journal-title":"PloS one"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T16:33:53Z","timestamp":1589819633000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188999"}},"subtitle":[],"editor":[{"given":"William B.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188999","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}